Michelle Beck - Palomar College

PROFILE
KEVIN A. KELLIHER
17931 Wheatridge Drive, Germantown, MD 20874
240.413.2564 kkelliher2012@kellogg.northwestern.edu
Biotechnology subject matter expert with more than 10 years of pharmaceutical, biologic, and medical device product
experience spanning multifunctional team leadership, alliance management, licensing diligence, pipeline market
assessments, regulatory strategy, and preclinical/clinical study development.
Areas of Expertise: Product Development, Client Relationship Management, Business Process Improvement Strategy and
Analytics
EDUCATION
THE KELLOGG SCHOOL OF MANAGEMENT, NORTHWESTERN UNIVERSITY, Evanston, IL
M.B.A., (Strategy and Finance Concentration) Degree expected December 2012
THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD
M.S., Biotechnology (Biotechnology Enterprise Concentration), 2003
FRANKLIN AND MARSHALL COLLEGE, Lancaster, PA
B.A., Biology, 1996
EXPERIENCE
BOOZ ALLEN HAMILTON, Rockville, MD 2008 – 2011
Associate, Health Strategy & Operations Team
• Identified and procured novel and follow-on work under Booz Allen Health account, including 17 new opportunities
from FY 2009-2010 valued at more than $15M.
• Applied operational strategy concepts in providing restructuring and pipeline assessments for commercial life science
organization, resulting in increased structural, informational, and decision rights efficiencies.
• Developed program recommendations for FDA senior leadership that enabled the Agency to develop transparent,
accurate, and repeatable resource estimates needed to fulfill its 1400 statutory responsibilities.
• Leader of the 2-year, 7-member Postmarketing Requirement/Postmarketing Commitment Annual Status Report and
Backlog Review Study commissioned by Congressional mandate, resulting in reducing the PMR/PMC open backlog
from 1400 to 600 and increased FDA’s internal database accuracy by 60%.
ICON DEVELOPMENT SOLUTIONS, Ellicott City, MD 2006 – 2008
Manager
• Consulted clients on diligence license examinations, clinical protocol programs, and product development strategies.
• Capitalized on two Small Business Unit (SBU) opportunities, increasing staff by 50 and expanding annual
department revenues to over $5M.
• Closed 100% of opportunities (5/5); awarded work in excess of $4.25M, a 150% increase over FY2007.
• Acted as lead on 17 consulting projects and FDA contact on behalf of 11 clients at the pre-clinical, clinical, and postcommercialization
stages.
NABI BIOPHARMACEUTICALS, Rockville, MD 2005 – 2006
Senior Associate
• Developed strategies to modify three pipeline products and four approved products.
• Developed and presented growth strategies to international human therapeutic regulatory agencies for StaphVax and
NicVax conjugate vaccine products.
DIGENE CORPORATION, Gaithersburg, MD 2001 – 2004
Associate, Senior Associate